PE20211818A1 - Composicion farmaceutica para administracion oral que comprende derivado de aminopirimidina o su sal - Google Patents

Composicion farmaceutica para administracion oral que comprende derivado de aminopirimidina o su sal

Info

Publication number
PE20211818A1
PE20211818A1 PE2021000495A PE2021000495A PE20211818A1 PE 20211818 A1 PE20211818 A1 PE 20211818A1 PE 2021000495 A PE2021000495 A PE 2021000495A PE 2021000495 A PE2021000495 A PE 2021000495A PE 20211818 A1 PE20211818 A1 PE 20211818A1
Authority
PE
Peru
Prior art keywords
pharmaceutical composition
oral administration
aminopyrimidine
derivative
salt
Prior art date
Application number
PE2021000495A
Other languages
English (en)
Inventor
Seongkyu Kim
Deokkyu Lee
Soo-Won Kim
Jun-Mo Yang
Yoong-Sik Park
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of PE20211818A1 publication Critical patent/PE20211818A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripcion proporciona una composicion farmaceutica para administracion oral que comprende: N-(5-(4-(4((dimetilamino)metil)-3-fenil-1Hpirazol-1-il)pirimidina-2-ilamino)-4-metoxi-2-morfolinofenil)acrilamida (Lazertinib) o su sal farmaceuticamente aceptable como un ingrediente activo; y una combinacion de celulosa microcristalina y manitol como un diluyente. El Lazertinib es un inhibidor selectivo de la proteina quinasa, particularmente, la proteina quinasa para un receptor del factor de crecimiento epidermico mutante, y se emplea en el tratamiento del cancer de pulmon de celulas no pequenas.
PE2021000495A 2018-10-18 2019-10-17 Composicion farmaceutica para administracion oral que comprende derivado de aminopirimidina o su sal PE20211818A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020180124171A KR20200043618A (ko) 2018-10-18 2018-10-18 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
PCT/IB2019/058862 WO2020079637A1 (en) 2018-10-18 2019-10-17 Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt

Publications (1)

Publication Number Publication Date
PE20211818A1 true PE20211818A1 (es) 2021-09-14

Family

ID=70282933

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021000495A PE20211818A1 (es) 2018-10-18 2019-10-17 Composicion farmaceutica para administracion oral que comprende derivado de aminopirimidina o su sal

Country Status (27)

Country Link
US (1) US20210322428A1 (es)
EP (2) EP4306113A3 (es)
JP (2) JP7369769B2 (es)
KR (2) KR20200043618A (es)
CN (1) CN113015521A (es)
AR (1) AR117655A1 (es)
AU (1) AU2019360446A1 (es)
BR (1) BR112021007061A2 (es)
CA (1) CA3116652A1 (es)
DK (1) DK3866767T3 (es)
EA (1) EA202191061A1 (es)
ES (1) ES2968966T3 (es)
FI (1) FI3866767T3 (es)
HR (1) HRP20231670T1 (es)
IL (1) IL282163A (es)
LT (1) LT3866767T (es)
MA (1) MA53927B1 (es)
MX (1) MX2021004457A (es)
PE (1) PE20211818A1 (es)
PH (1) PH12021550687A1 (es)
PL (1) PL3866767T3 (es)
PT (1) PT3866767T (es)
RS (1) RS65012B1 (es)
SG (1) SG11202103057RA (es)
SI (1) SI3866767T1 (es)
TW (1) TWI831848B (es)
WO (1) WO2020079637A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020230091A1 (en) 2019-05-14 2020-11-19 Janssen Biotech, Inc. Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
TW202207940A (zh) * 2020-04-14 2022-03-01 美商健生生物科技公司 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物
EP4349835A1 (en) 2021-06-01 2024-04-10 Hangzhou Solipharma Co., Ltd. Hydrate crystal form of lazertinib methanesulfonate, preparation method therefor and use thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL193673B1 (pl) * 1998-07-20 2007-03-30 Smithkline Beecham Corp Bezpostaciowa sól amonowa eprosartanu,jej granulat i biologicznie ulepszony preparat oraz sposoby ich wytwarzania i zastosowanie
DE10319450A1 (de) 2003-04-30 2004-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Formulierung des Telmisartan Natriumsalzes
ES2359377T3 (es) * 2006-10-27 2011-05-23 Fmc Corporation Celulosa microcristalina coprocesada y alcohol de azúcar como excipiente para formulaciones de comprimidos.
JP5410290B2 (ja) 2006-10-27 2014-02-05 エフ エム シー コーポレーション 共処理組成物とその製造方法、打錠可能な錠剤処方物、錠剤の製造方法及び錠剤
WO2013016694A2 (en) * 2011-07-27 2013-01-31 Cornell University Methods for rna detection and quantification
KR20140063808A (ko) 2011-09-14 2014-05-27 셀진 코포레이션 시클로프로판카르복실 산｛２-[(１s)-１-(３-에톡시-４-메톡시-페닐)-２-메탄술포닐-에틸]-３-옥소-２,３-디하이드로-１h-이소인돌-４-일｝-아마이드의 제제
CN104039319B (zh) 2011-11-29 2017-12-29 吉利德制药有限责任公司 用于治疗hcv的组合物和方法
WO2014175986A2 (en) * 2013-04-23 2014-10-30 RevOrtho LLC A method and system for modular hip resurfacing
GB201400034D0 (en) 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
SG11201701960XA (en) * 2014-10-13 2017-04-27 Yuhan Corp Compounds and compositions for modulating egfr mutant kinase activities
KR102606253B1 (ko) 2014-12-16 2023-11-27 시그날 파마소티칼 엘엘씨 2-(tert-부틸아미노)-4-((1r,3r,4r)-3-하이드록시-4-메틸사이클로헥실아미노)-피리미딘-5-카복사마이드의 제형
CN104788427B (zh) * 2015-02-05 2017-05-31 上海泓博智源医药股份有限公司 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用
CN107847448A (zh) 2015-05-22 2018-03-27 诺华股份有限公司 药物组合物
KR102488488B1 (ko) 2015-10-07 2023-01-12 쿄와 기린 가부시키가이샤 아릴알킬아민 화합물 함유 의약 조성물
CA3019391A1 (en) 2016-04-07 2017-10-12 Chemocentryx, Inc. Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
AR111469A1 (es) * 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
TW202207940A (zh) * 2020-04-14 2022-03-01 美商健生生物科技公司 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物

Also Published As

Publication number Publication date
SI3866767T1 (sl) 2024-02-29
AR117655A1 (es) 2021-08-25
WO2020079637A1 (en) 2020-04-23
ES2968966T3 (es) 2024-05-14
JP2024016052A (ja) 2024-02-06
EP3866767A4 (en) 2022-07-20
DK3866767T3 (da) 2024-01-29
US20210322428A1 (en) 2021-10-21
JP2022504943A (ja) 2022-01-13
CN113015521A (zh) 2021-06-22
EA202191061A1 (ru) 2021-07-09
FI3866767T3 (fi) 2024-01-30
SG11202103057RA (en) 2021-05-28
KR20210061457A (ko) 2021-05-27
WO2020079637A9 (en) 2020-07-23
TW202034903A (zh) 2020-10-01
EP3866767B1 (en) 2023-11-29
BR112021007061A2 (pt) 2021-07-20
HRP20231670T1 (hr) 2024-03-15
PL3866767T3 (pl) 2024-04-02
CA3116652A1 (en) 2020-04-23
EP3866767A1 (en) 2021-08-25
EP4306113A2 (en) 2024-01-17
EP4306113A3 (en) 2024-02-14
MA53927B1 (fr) 2023-12-29
PT3866767T (pt) 2024-01-18
IL282163A (en) 2021-05-31
RS65012B1 (sr) 2024-01-31
PH12021550687A1 (en) 2022-02-14
LT3866767T (lt) 2023-12-27
AU2019360446A1 (en) 2021-04-22
TWI831848B (zh) 2024-02-11
JP7369769B2 (ja) 2023-10-26
MA53927A (fr) 2021-09-15
KR20200043618A (ko) 2020-04-28
MX2021004457A (es) 2021-07-07

Similar Documents

Publication Publication Date Title
PE20211818A1 (es) Composicion farmaceutica para administracion oral que comprende derivado de aminopirimidina o su sal
ECSP20013248A (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
CO2017008862A2 (es) Composiciones farmacéuticas que comprenden n-(3,5-dimetoxifenil)-n’-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il-quinoxalin-6-il]etano-1,2-diamina
ES2557303T3 (es) Agente terapéutico para la estenosis del canal espinal
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
BR112016008016A2 (pt) inibidores de kras g12c
DK2324008T3 (da) Diarylpyrazol som protein kinase inhibitorer
NO20065638L (no) Formuleringer med kontrollert frigivelse inneholdende vardenafil
RS54651B1 (en) JANUS KINAS INHIBITORS for the treatment of dry eye and other eye diseases
EA200970595A1 (ru) Производные замещенных индазолов, активные в качестве ингибиторов киназ
NO20080164L (no) N-(pyridin-2-yl)-sulfonamidderivater
NO331166B1 (no) Inhibitorer av tyrosinkinaser, fremgangsmate for fremstilling derav, farmasoytisk preparat samt anvendelse av forbindelsene
BR112015029512A8 (pt) derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas
WO2020115555A3 (en) Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
DE602004017194D1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
NO20080670L (no) Substituerte piperaziner som metabotrofiske glutamatreseptorantagonister
BR112017010439A2 (pt) composto, composição farmacêutica, combinação farmacêutica, kit, métodos para controle de uma doença fúngica em uma planta e para prevenção ou tratamento de doença fúngica em um indivíduo, e, uso de um composto
EA201100358A1 (ru) Дабигатран для чрескожной хирургической катетеризации сердца
BR112019006228A2 (pt) tratamento de câncer de próstata
WO2018005519A3 (en) Cancer treatment combinations
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
BR112022020609A2 (pt) Composição farmacêutica para administração oral que compreende derivado de aminopirimidina ou sal, hidrato ou solvato farmaceuticamente aceitável do mesmo
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
CL2021003032A1 (es) Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton